[A22-45] Mepolizumab (hypereosinophilic syndrome) – Addendum to Commission A21-152
Last updated 20.05.2022
Project no.:
A22-45
Commission:
Commission awarded on 12.04.2022 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Haematology
Add-on therapy for adult patients with inadequately controlled hypereosinophilic syndrome (HES) without an identifiable non-haematological secondary cause
After addendum: Hint of major added benefit
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
| Project no. | Title | Status |
|---|---|---|
| A21-152 | Mepolizumab (hypereosinophilic syndrome) - Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2022-05-20 A G-BA decision was published.